Litigation Details for Biogen International GMBH v. Sandoz Inc. (D. Colo. 2017)
✉ Email this page to a colleague
Biogen International GMBH v. Sandoz Inc. (D. Colo. 2017)
| Docket | ⤷ Sign Up | Date Filed | 2017-06-30 |
| Court | District Court, D. Colorado | Date Terminated | |
| Cause | 15:1126 Patent Infringement | Assigned To | Michael E. Hegarty |
| Jury Demand | None | Referred To | |
| Patents | 6,509,376; 7,320,999; 8,399,514 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Biogen International GMBH v. Sandoz Inc.
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Biogen International GMBH v. Sandoz Inc. (D. Colo. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-06-30 | 1 | is an action for patent infringement of U.S. Patent Nos. 6,509,376 (“the ’376 patent”), 7,320,999 (“the…“the ’999 patent”) and 8,399,514 (“the ’514 patent”) arising under the patent laws of the United States…Sandoz. FIRST COUNT FOR PATENT INFRINGEMENT (’376 PATENT) 13. Biogen realleges, … 14. The U.S. Patent and Trademark Office (“PTO”) issued the ’376 patent on January 21, 2003,… owner of the ’376 patent by virtue of assignment. 16. The ’376 patent expires on October | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
